Close
Smartlab Europe
Achema middle east

Stellar Biotechnologies develops aquaculture system for KLH manufacturing

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Teva, Royalty Pharma $500M Deal to Advance Autoimmune Drug

Teva Pharmaceutical Industries and Royalty Pharma have signed a...

Pierre Fabre, Iktos Launch AI-Driven Oncology Drug Discovery

An integrated partnership has been formed between Pierre Fabre...

Revvity and Lilly Expand Lilly TuneLab Access via Signals

Revvity, Inc. announced a collaboration with Eli Lilly and...
- Advertisement -

Stellar Biotechnologies has developed a controlled, commercial-scale aquaculture system for fully sustainable Keyhole Limpet Hemocyanin (KLH) manufacturing.

The land-based aquaculture system is designed to support multiple generations of all stages of Megathura crenulata’s life cycle, producing pharmaceutical grade KLH in commercial scale.

Stellar president and CEO Frank Oakes said, “This is about controlling the lifecycle of the source animal, allowing Stellar to grow new generations of limpets spawned by parents that have never seen the ocean, thus ensuring that the pharmaceutical industry has ample supply of GMP grade KLH, made under controlled conditions, while protecting survival of a wild species.”

The great keyhole limpet is the common name of mollusk Megathura crenulata, which is KLH’s marine source.

Stellar aquaculture manager Brandon Lincucum said, “We’ve set the benchmark for KLH manufacturing and we’re proud to represent these new aquaculture and environmental milestones as well.”

Latest stories

Related stories

Teva, Royalty Pharma $500M Deal to Advance Autoimmune Drug

Teva Pharmaceutical Industries and Royalty Pharma have signed a...

Pierre Fabre, Iktos Launch AI-Driven Oncology Drug Discovery

An integrated partnership has been formed between Pierre Fabre...

Revvity and Lilly Expand Lilly TuneLab Access via Signals

Revvity, Inc. announced a collaboration with Eli Lilly and...

Amgen Eyeing Preclinical Blood Cancer Program to Its Skills

Amgen is going ahead and adding Dark Blue to...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »